Indi Molecular

Indi Molecular, located in Culver City, CA, specializes in the development of synthetic small molecule targeted oncology therapeutics aimed at treating ovarian cancer and KRAS G12D expressing pancreatic cancers. Utilizing a breakthrough synthetic protein chemistry platform known as Protein Catalyzed Capture (PCC), the company creates small synthetic peptide replacements for traditional antibody-based therapies.

The therapeutics produced by Indi Molecular exhibit specific targeting capabilities, demonstrating picomolar to low nanomolar binding affinities and fast synthesis processes. Their innovative approach ensures stable, water-soluble molecules that retain functional activity in vivo, potentially offering significant therapeutic effects against both intracellular and extracellular targets.

Generated from the website